Roivant Sciences Ltd. $ROIV Shares Acquired by FNY Investment Advisers LLC

FNY Investment Advisers LLC grew its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 104.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,533 shares of the company’s stock after acquiring an additional 9,997 shares during the period. FNY Investment Advisers LLC’s holdings in Roivant Sciences were worth $220,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of ROIV. GAMMA Investing LLC grew its stake in shares of Roivant Sciences by 83.0% in the first quarter. GAMMA Investing LLC now owns 6,493 shares of the company’s stock worth $66,000 after acquiring an additional 2,945 shares in the last quarter. Penn Davis Mcfarland Inc. grew its stake in shares of Roivant Sciences by 3.5% in the first quarter. Penn Davis Mcfarland Inc. now owns 1,707,232 shares of the company’s stock worth $17,226,000 after acquiring an additional 58,206 shares in the last quarter. GF Fund Management CO. LTD. grew its stake in shares of Roivant Sciences by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 18,641 shares of the company’s stock worth $188,000 after acquiring an additional 3,356 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Roivant Sciences by 16.3% in the first quarter. Bank of New York Mellon Corp now owns 4,000,181 shares of the company’s stock worth $40,362,000 after acquiring an additional 560,641 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Roivant Sciences by 10.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 102,478 shares of the company’s stock worth $1,034,000 after acquiring an additional 9,357 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Eric Venker sold 118,418 shares of the business’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $17.06, for a total value of $2,020,211.08. Following the completion of the sale, the chief executive officer directly owned 1,504,959 shares of the company’s stock, valued at $25,674,600.54. The trade was a 7.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 5,228,958 shares of company stock valued at $76,447,638 over the last three months. 10.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ROIV has been the subject of a number of analyst reports. Bank of America boosted their target price on shares of Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a research note on Thursday, September 18th. Jefferies Financial Group boosted their target price on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. Citigroup initiated coverage on shares of Roivant Sciences in a research note on Tuesday, September 2nd. They set a “buy” rating and a $16.00 target price for the company. The Goldman Sachs Group boosted their target price on shares of Roivant Sciences from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. Finally, Guggenheim boosted their target price on shares of Roivant Sciences from $15.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.94.

Roivant Sciences Price Performance

Shares of ROIV opened at $17.96 on Thursday. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $18.06. The stock has a market cap of $12.26 billion, a PE ratio of -25.66 and a beta of 1.20. The firm has a fifty day moving average price of $14.35 and a 200 day moving average price of $12.17.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.